• About us
• Contact

Advertisement

Organisation › Details

Reata Pharmaceuticals Inc. (Nasdaq: RETA)

Reata is a global biopharmaceutical company committed to developing and commercializing novel therapeutics for patients with serious or life-threatening diseases with few or no approved therapies. Reata focuses on molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s first product, SKYCLARYS® (omaveloxolone) has been approved by the FDA for the treatment of Friedreich’s ataxia and is under review in Europe by the EMA. In addition, Reata is developing cemdomespib for the treatment of patients with diabetic neuropathic pain. Cemdomespib is an investigational drug, and its safety and efficacy have not been established by any regulatory agency. *

 

	Start	2002-01-01 established
	Group	Biogen (Group)
	Industry	small-molecule drug
	Industry 2	Skyclarys®
	Person	Huff, Warren (Reata Pharmaceuticals 202307 CEO)
	Street	5320 Legacy Drive
	City	75024 Plano, TX
	Tel	+1-972-865-2219
		Address record changed: 2023-08-23
Basic data	Employees	n. a.
		* Document for »About Section«: Biogen Inc.. (7/28/23). "Press Release: Biogen to Acquire Reata Pharmaceuticals". Cambridge, MA & Plano, TX.
		Record changed: 2023-08-24

Advertisement

More documents for Biogen (Group)

• [1] Jeito Capital. (5/22/24). "Press Release: Jeito Capital Announces Acquisition of Portfolio Company HI-Bio by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 Billion". Paris....
• [2] Biogen Inc.. (5/22/24). "Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences". Cambridge, MA & South San Francisco, CA....
• [3] Human Immunology Biosciences, Inc. (HI-Bio). (1/4/24). "Press Release: HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases". South San Francisco, CA....
• [4] Biogen Inc.. (7/28/23). "Press Release: Biogen to Acquire Reata Pharmaceuticals". Cambridge, MA & Plano, TX....
• [5] Anjarium Biosciences AG. (7/12/22). "Press Release: Anjarium Biosciences Appoints Experienced Industry Executives Samantha Vieira as Chief Operating Officer and Nate Massari as Chief Business Officer". Zurich....
• [6] MorphoSys AG. (6/14/22). "Press Release: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210". Planegg & South San Francisco, CA....
• [7] Weinreb, Gali [Globes]. (5/3/22). "News: Sanara Sets Up $100m VC Fund to Transform Healthcare"....
• [8] Cevec Pharmaceuticals GmbH. (1/8/21). "Press Release: Cevec Announces New License Agreement for Its AAV Manufacturing Technology Elevecta in Gene Therapy". Cologne....
• [9] ViGeneron GmbH. (1/5/21). "Press Release: ViGeneron Signs Global Collaboration Agreement for Ophthalmic Gene Therapy Development". Munich....
• [10] Merck KGaA. (12/11/20). "Press Release: Bavencio (avelumab) Receives Positive CHMP Opinion for First-line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma". Darmstadt....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.